Drug profile · INN
donanemab
KISUNLA
donanemab (KISUNLA) is a beta amyloid a4 protein disrupting agent.
Drug details — donanemab
- Class
- Nervous system (N06)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
donanemab (KISUNLA) is a beta amyloid a4 protein disrupting agent.
Key facts
Mechanism of action
Beta amyloid A4 protein disrupting agent
Primary target: Amyloid-beta precursor protein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease
The FDA has approved Eli Lilly’s Kisunla (donanemab-azbt) for Alzheimer’s disease, with use to begin in patients with mild cognitive impairment or mild dementia. The decision is a major catalyst for BD teams, investors, and analysts tracking the early Alzheimer’s treatment space.
FDA Breakthrough Therapy Designations: Advancing Alzheimer's Drug Development
Learn how FDA Breakthrough Therapy Designations are transforming Alzheimer's drug development, focusing on innovative treatments like Aducanumab.
FDA Grants Accelerated Approval to Eli Lilly's Donanemab for Alzheimer's
Eli Lilly's Donanemab receives accelerated FDA approval for Alzheimer's, offering new hope for patients and families affected by this challenging disease.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is donanemab?
donanemab (KISUNLA) is a beta amyloid a4 protein disrupting agent.
What is the brand name for donanemab?
KISUNLA is a marketed brand name for donanemab. Check FDA Drugs@FDA for the current US label holder and prescribing information.